Disposable Technologies for Fill-Finish of Clinical-Trial Materials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Disposable Technologies for Fill-Finish of Clinical-Trial Materials
The author examines the use and advantages of disposable technologies in the fill–finish of sterile pharmaceutical products and how these technologies can reduce costs and time in producing clinical-trial materials.


Pharmaceutical Technology
Volume 34, pp. s22-s25

Converting to a disposable system

Changing an existing reusable system to one that takes advantage of disposable technologies may not always seem to be an attractive option. The investment already made in existing equipment may restrict the implementation of disposable technologies in some facilities. However, even if it is considered to be impractical to invest in an entire disposable system, advantages can be gained from introducing elements of the disposable systems previously described. For example, increasing the use of disposable vessels (e.g., glass or plastic bottles and flexible bags) will potentially decrease turnaround times by reducing cleaning requirements.

Conclusions

Disposable technologies in the manufacture of clinical supplies of biopharmaceuticals offer the benefit of reducing cost, time, and risk. Some disposable technologies can be introduced into an existing facility quickly and at minimal cost. Savings can be achieved in the manufacturing process, and time efficiencies can be realized. By taking advantage of the removal of the requirement for cleaning verification when a fully disposable manufacturing equipment train is used, the time to get the product to the clinical trial can be reduced by as much as two months. For some companies, this improvement may be the most significant benefit of all.

References

1. A. Sinclair and M. Monge, BioProcess Intl. 3 (9), s51–s55 (2005).

2. M. Fuller and H. Pora, BioProcess Intl. 6 (10), 30–36 (2008).

3. G. Hodge, BioProcess Intl. 2 (5), 74–80 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here